+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Human Growth Hormone Market 2018-2022 - Product Image

Global Human Growth Hormone Market 2018-2022

  • ID: 4721482
  • Report
  • December 2018
  • Region: Global
  • 110 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Pfizer
  • MORE
Increasing incidence and prevalence of growth hormone disorders due to the growth hormone deficiency is expected to drive the human growth hormone market over the forecast period. Moreover, various indications fall under the growth hormone disorders such as turner syndrome, growth hormone deficiency, acromegaly, Noonan syndrome, gigantism, and many more. The analysts have predicted that the human growth hormone market will register a CAGR of almost 4% by 2022.

Market Overview

Strong pipeline of human growth hormone

Many leading companies such as Novo Nordisk, Merck, and Pfizer have a strong pipeline in their portfolio for treating various growth hormone disorders. All these factors are expected to drive the global human growth hormone market during the forecast period.

Poor patient adherence

The poor patient adherence for human growth hormone due to uneasiness with growth hormone administration will impact the treatment adherence and results.

For the detailed list of factors that will drive and challenge the growth of the human growth hormone market during the 2018-2022, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Novo Nordisk and Pfizer, the competitive environment is quite intense. Factors such as the strong pipeline of human growth hormone and the increasing incidence and prevalence of growth hormone disorders, will provide considerable growth opportunities to human growth hormone manufactures. Eli Lilly, F. Hoffmann-La Roche, Novo Nordisk, and Pfizer are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE ANALYSIS
  • Human growth hormone pipeline analysis
PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: MARKET SEGMENTATION BY DRUG TYPE
  • Segmentation by drug type
PART 09: MARKET SEGMENTATION BY APPLICATION
  • Segmentation by application
  • Comparison by application
  • Growth hormone deficiency - Market size and forecast 2017-2022
  • ISS - Market size and forecast 2017-2022
  • Turner syndrome - Market size and forecast 2017-2022
  • PWS - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by application
PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 14: MARKET TRENDS
  • Increasing incidence of growth disorders
  • No impact of biosimilar entry into market
  • Advanced technologies
PART 15: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 16: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Pfizer
PART 17: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global human growth hormone market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs under Phase III stage of development 2017-2018
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Application - Market share 2017-2022 (%)
Exhibit 20: Comparison by application
Exhibit 21: Growth hormone deficiency - Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Growth hormone deficiency - Year-over-year growth 2018-2022 (%)
Exhibit 23: ISS- Market size and forecast 2017-2022 ($ mn)
Exhibit 24: ISS - Year-over-year growth 2018-2022 (%)
Exhibit 25: Turner syndrome - Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Turner syndrome - Year-over-year growth 2018-2022 (%)
Exhibit 27: PWS - Market size and forecast 2017-2022 ($ mn)
Exhibit 28: PWS - Year-over-year growth 2018-2022 (%)
Exhibit 29: Others - Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Others - Year-over-year growth 2018-2022 (%)
Exhibit 31: Market opportunity by application
Exhibit 32: Customer landscape
Exhibit 33: Global - Market share by geography 2017-2022 (%)
Exhibit 34: Regional comparison
Exhibit 35: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 36: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in Americas
Exhibit 38: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 39: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in EMEA
Exhibit 41: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 42: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 43: Top 3 countries in APAC
Exhibit 44: Market opportunity
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Eli Lilly - Overview
Exhibit 51: Eli Lilly - Business segments
Exhibit 52: Eli Lilly - Organizational developments
Exhibit 53: Eli Lilly - Geographic focus
Exhibit 54: Eli Lilly - Segment focus
Exhibit 55: Eli Lilly - Key offerings
Exhibit 56: Eli Lilly - Key customers
Exhibit 57: F. Hoffmann-La Roche - Overview
Exhibit 58: F. Hoffmann-La Roche - Business segments
Exhibit 59: F. Hoffmann-La Roche - Organizational developments
Exhibit 60: F. Hoffmann-La Roche - Geographic focus
Exhibit 61: F. Hoffmann-La Roche - Segment focus
Exhibit 62: F. Hoffmann-La Roche - Key offerings
Exhibit 63: F. Hoffmann-La Roche - Key customers
Exhibit 64: Novo Nordisk - Overview
Exhibit 65: Novo Nordisk- Business segments
Exhibit 66: Novo Nordisk - Organizational developments
Exhibit 67: Novo Nordisk - Geographic focus
Exhibit 68: Novo Nordisk - Segment focus
Exhibit 69: Novo Nordisk- Key offerings
Exhibit 70: Pfizer - Overview
Exhibit 71: Pfizer - Business segments
Exhibit 72: Pfizer - Organizational developments
Exhibit 73: Pfizer - Geographic focus
Exhibit 74: Pfizer - Segment focus
Exhibit 75: Pfizer - Key offerings
Exhibit 76: Pfizer - Key customers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Pfizer
  • MORE
Global Human Growth Hormone Market 2018-2022

The analyst recognizes the following companies as the key players in the global human growth hormone market: Eli Lilly, F. Hoffmann-La Roche, Novo Nordisk, and Pfizer.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing incidence and prevalence of growth hormone disorders.”

According to the report, one of the major drivers for this market is the strong pipeline of human growth hormone.

Further, the report states that one of the major factors hindering the growth of this market is the poor patient adherence.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll